静脉滴注潘妥拉唑对健康成人24小时胃内pH变化的影响

目的探讨质子泵阻滞剂潘妥拉唑对健康成人24h胃内pH变化的影响.方法利用DigitrapperMKⅢ动态pH监测仪观察10名健康志愿者24h胃内pH变化节律,1周后,分别于晨8时静脉滴注潘妥拉唑80mg,连续2d,并于第2天给药后立即进行24h胃内pH监测.结果健康成人24h胃内pH平均值为2.21±0.86,pH＞4总时间百分比为(15.75±13.60)%,24h胃内pH变化曲线下面积为1.90×105±0.80×105.静脉滴注潘妥拉唑后,24h胃内pH平均值、pH＞4总时间百分比、24h胃内pH变化曲线下面积分别升至7.18±1.06、(93.41±8.43)%及6.20×105±0.90×105(P＜0.01).结论正常人24h胃内pH变化节律证实,潘妥拉唑有较强的抑制胃酸分泌作用.     

奥美拉唑镁肠溶片与奥美拉唑胶囊治疗消化性溃疡的临床随机对照研究

目的　验证奥美拉唑镁肠溶片与奥美拉唑胶囊治疗消化性溃疡的生物等效性及评价其不良反应。方法　采用随机对照和开放试验的方法治疗经胃镜检查证实的消化性溃疡共 171例 ,其中奥美拉唑镁肠溶片组 (试验组 ) 68例 ,胃溃疡 2 1例 ,十二指肠溃疡 47例 ;奥美拉唑胶囊组 (对照组 ) 67例 ,其中胃溃疡 2 1例 ,十二指肠溃疡 46例 ;开放试验组 3 6例 ,其中十二指肠溃疡 2 9例 ,胃溃疡 7例。结果　试验组中胃溃疡的愈合率和总有效率分别为 80 9%和 10 0 %十二指肠溃疡的愈合率和总有效率分别为87 2 %和 97 8% ;对照组中胃溃疡的愈合率和总有效率为 85 7%和 95 2 % ,十二指肠溃疡的愈合率和总有效率为 84 7%和 97 8% ;开放试验组中胃溃疡的愈合率和总有效率均为 10 0 0 %十二指肠溃疡的愈合率和总有效率分别为 86 2 %和 10 0 % ;试验组中疼痛消失率及其他消化道症状的消失率在胃溃疡为 95 2 %和 89 0 %在十二指肠溃疡则为 97 8%和 98 3 % ;对照组中疼痛及其他消化道症状的消失率在胃溃疡为 95 2 %和 92 7% ,在十二指肠溃疡为 97 8%和 98 7%。两组在愈合率、总有效率、疼痛消失率和其他消化道症状消失率方面相比均无显著差别 (P >O 0 5 )。两组在治疗过程中均未见明显的不良反应。结论　奥美拉唑镁肠溶片与奥     

雷尼替丁和奥美拉唑对消化性溃疡出血患者胃内24小时pH珠影响

１．１研究对象 经胃镜及病理切片证实为消化性溃疡出血者共３０例,随机分为２组。雷尼替丁组１６例,年龄２０~７０岁,男１３例,女３例,十二指肠球部溃疡１０例,胃溃疡４例,复合性溃疡２例,给雷尼替丁０．１５ｇ＋５%ＧＳ２５０ｍｌ静滴。奥美拉唑组１４例,年龄１８~     

埃索美拉唑与奥美拉唑对胃食管反流病24小时胃内pH效果比较

维持胃内pH >4是有效治疗胃食管反流病 (GERD)的关键。 4 0mg埃索美拉唑是第一个光学异构体质子泵抑制剂 (PPI) ,已被证实较 2 0mg奥美拉唑有更显著的抑酸效果。此项研究的目的在于比较每天 1次埃索美拉唑 4 0mg与奥美拉唑 4 0mg对症状性GERD病人胃酸的影响。在这项开放交叉研究中 ,130例症状性GERD病人接受每天 1次埃索美拉唑 4 0mg或奥美拉唑 4 0mg连续 5d的治疗。在每个疗程的第 1天和第 5天进行 2 4h胃内pH监测。接受埃索美拉唑 4 0mg的病人第 1天和第 5天的 2 4h胃内pH >4的时间显著长于奥美拉唑 4 0mg(第 1天 :4 8.6 %比 4 0 …     

十二指肠溃疡患者24小时胃内pH节律特点

胃酸是造成胃十二指肠黏膜损害的主要因素 ,在消化性溃疡 ,尤其是十二指肠溃疡 (ＤＵ)的发生中起重要作用 ,它可直接或通过激活胃蛋白酶原引起胃肠黏膜的损伤。已知ＤＵ患者常有胃酸分泌的异常如基础胃酸分泌量和最大分泌量的增高等。近来我们应用胃腔内微电极 ,动态监测ＤＵ患者胃内 ｐＨ值的变化 ,以进一步了解该类患者胃酸分泌的生理变化和昼夜节律特点。对象和方法一、对象包括经内镜检查证实为ＤＵ活动期的患者 2 9例 ,男 2 4例 ,女 5例 ,年龄 (45 .8± 11.6 )岁 ;慢性胃炎 (ＣＧ) 18例 ,男 13例 ,女 5例 ,年龄 (5 0 .0± 16 .5 )岁 ;…     

雷贝拉唑对胃溃疡患者胃内pH值的影响

目的　评价顿服雷贝拉唑 10mg对胃溃疡患者的抑酸效果和症状缓解情况 ,并以奥美拉唑 2 0mg作为对照。 方法　采用随机、平行、双盲临床对照研究 ,患者随机进入雷贝拉唑组和奥美拉唑组。结果　 (1)两组用药后症状均明显改善 ,但治疗 1d后症状改善的程度差异无显著性 (P >0 0 5 ) ;(2 )两组抑酸药物的起效时间均在用药后 2h ;用药后 1h和 2h ,两组患者胃内pH值差异无显著性 (P >0 0 5 ) ;(3)雷贝拉唑组 2 4h总的、夜间 pH >4及夜间 pH >3的百分比明显高于奥美拉唑组(P <0 0 5 ) ,而白天pH >4和 pH >3及总的 pH >3的百分比两组之间差异无显著性 (P >0 0 5 ) ;(4 )雷贝拉唑组白天、夜间 pH >4及 2 4h总的、白天和夜间pH >3超过 30 %的百分率明显高于奥美拉唑组 (P <0 0 5 ) ,而只有总的pH >4超过 30 %的百分率 ,两组之间比较差异无显著性 (P >0 0 5 ) ;(5 )雷贝拉唑组无反应率明显低于奥美拉唑组 (7 8%比 16 4 % ) ,两组比较差异有显著性 (P <0 0 5 )。结论　雷贝拉唑顿服能有效缓解消化性溃疡症状 ,其抑酸效果优于奥美拉唑     

奥美拉唑和硫糖铝治疗十二指肠球部溃疡胃内24小时pH监测

对３０例十二指肠球部溃疡患者，分别投予奥美拉唑并以硫糖铝作为对照，用单昌体锑电极监测服药前后胃内２４小时ＰＨ变化，观察奥美拉唑对胃酸分泌的影响。分别在２４小时、８：００－２０：００时，和２０：００－８：００时的三个时间段进行分析。结果显示：观察的ＰＨ指标，在奥美拉唑组服药后明显升高（Ｐ均＜０．００１），硫糖铝组服药前后无变化（Ｐ均＞０．０５），奥美拉唑与硫糖铝组比较，差异显著（Ｐ均＜０．００１），     

携带式食管,胃24小时pH动态监测

食管２４小时ｐＨ动态监测在胃、食管返流疾病中已广泛应用。近年来，对胃２４小时ｐＨ动态监测亦引起临床界重视，目前主要用于判定抗酸药以及不同给药时间的抑酸效果，是临床药理及判断胃及酸相关性疾病的一个重要检查方法。     

三种奥美拉唑胶囊健康人的生物利用度及其对胃内24小时pH值的影响

目的 比较３种奥美拉唑产品（洛赛克、奥克、奥美拉唑）４０ｍｇ在健康人的生物利用度及对胃内２４ＰＨ值的影响。方法 交叉试验设计：１８例健康志原者（男１２例,女６例）被随机分成３组,每组交叉服用洛塞克、奥克、奥美拉唑胶囊１次４０ｍｇ,交叉间隔时间７天。结果 药代动力学研究结果表明相对于奥克胶囊与奥美拉唑胶囊,洛赛克胶囊有吸收速度快、血药浓度高与持续时间长及生物利用度高的优点。胃内２４Ｐ俞 不同胶囊服用     

Effect of repeated boluses of intravenous omeprazole and primed infusions of ranitidine on 24-hour intragastric pH in healthy human subjects

The aim of this study was to identify dosage regimens using intravenous omeprazole and ranitidine that would elevate and consistently maintain intragastric pH>6 in the first 24 hr of therapy. In 19 healthy, fasting human subjects using continuous 24-hr gastric pH-metry, we studied two dosages of primed infusions of ranitidine (50 mg bolus followed by infusion of either 3 or 6 mg/kg body wt/24 hr) and six regimens of intravenous omeprazole (80–200 mg in 24 hr in two to five boluses). Only the two ranitidine infusions and high doses of omeprazole (≥160 mg/day as four or five boluses) raised the intragastric median pH above 5.4. There was no significant difference in the median intragastric pH after high dose ranitidine and high doses of omeprazole. Considerable interindividual variation in intragastric pH was observed after omeprazole therapy. The percentage of intragastric pH>6.0 during the 24-hr study was lower after omeprazole (35–42%) than after high-dose ranitidine (58%). We conclude that it is possible to raise intragastric pH>6.0 by use of either primed ranitidine infusion or by repeated boluses of omeprazole. However, maintenance of this high pH in the first 24 hr is difficult with both, more so with omeprazole.     

Intravenous omeprazole: effect on 24-hour intragastric pH in duodenal ulcer patients

This study was aimed to identify an intravenous dosage regime of omeprazole which would sufficiently suppress acid secretion to maintain intragastric pH greater than 4 continuously. Thirteen duodenal ulcer patients in remission received omeprazole in daily intravenous doses ranging from 40 to 200 mg. Doses were successively increased as dictated by patient response. The intragastric pH data indicated that omeprazole given in twice or thrice daily regimes in total intravenous amounts of 200, 160 and 160 mg over a consecutive 3-day period markedly inhibited acid secretion and maintained intragastric pH greater than 4 with few and short-term exceptions.     

Effect of esomeprazole 40 mg vs omeprazole 40 mg on 24-hour intragastric pH in patients with symptoms of gastroesophageal reflux disease

Maintenance of intragastric pH > 4 is vital for effective management of gastroesophageal reflux disease (GERD). Esomeprazole 40 mg, the first proton pump inhibitor developed as an optical isomer, demonstrates improved acid inhibition over omeprazole 20 mg. Our aim was to compare esomeprazole 40 mg with omeprazole 40 mg, once-daily, on intragastric acidity in patients with symptoms of GERD. In this open-label, crossover study, 130 patients with symptoms of GERD received esomeprazole 40 mg or omeprazole 40 mg once-daily for five days. The 24-hr intragastric pH was monitored on days 1 and 5 of each treatment period. The mean percentage of the 24-hr period with intragastric pH > 4 was significantly greater (P < 0.001) with esomeprazole 40 mg than with omeprazole 40 mg on days 1 (48.6% vs 40.6%) and 5 (68.4% vs 62.0%). Interpatient variability was significantly less with esomeprazole than omeprazole. Esomeprazole was well tolerated. In conclusion, esomeprazole 40 mg provides more effective acid control than twice the standard dose of omeprazole.     

The effect of the H2-antagonist niperotidine on intragastric acidity in healthy subjects undergoing 24-hour pH-monitoring

The effects of niperotidine, a novel histamine H2-receptor antagonist, on nocturnal gastric acid secretion in healthy volunteers, have been investigated. Twenty subjects were randomly assigned to the placebo (M:F = 7:3; Age 34 +/- SD3 yrs) or to the niperotidine-treated group (M:F = 7:3; Age: 37 +/- 6 yrs) in which 460 mg were administered at 22.00. Intragastric acidity was assessed by means of 24-hour pH-measurement (10.00-22.00) using sensitive antimony monocrystalline electrodes. The percentage of daytime gastric acidity (prandial and interprandial) was similar in both groups (median; interquartile range): placebo group 87.5; 69.5-90.1 vs niperotidine 85.8; 59-89.1. Niperotidine increased the intragastric pH during the period 22.00-10.00. The percentage of time above pH 4 was higher in the treated group (28.4; 14.8-50.7% vs 7.4; 1.4-10.7%; p less than 0.02). The duration of niperotidine action was 5 to 7 hours. The nocturnal pH frequency curve after niperotidine was shifted toward alkaline values with a decrease of acidity in the pH range 1-2 (p less than 0.04). We conclude that a bedtime dose of niperotidine inhibits nocturnal gastric acid secretion in healthy subjects.     

埃索美拉唑对健康志愿者抑制胃泌酸的药效学研究

目的　比较埃索美拉唑与雷贝拉唑对健康志愿者抑制胃泌酸的效果及安全性。方法　 36名健康志愿者随机分为两组 ,分别口服埃索美拉唑 4 0mg或雷贝拉唑 10mg ,每日 1次 ,连续 5d ,经过14d的洗脱期后 ,交叉口服雷贝拉唑 10mg或埃索美拉唑 4 0mg ,每日 1次 ,连续 5d。分别于服药首日及第 5天连续测定 2 4h胃内 pH ,并以PCR方法鉴定细胞色素 (CYP) 2C19基因型。 结果　埃索美拉唑组服药后首日最初 4、2 4h和第 5天 2 4h胃内pH >4 .0的时间百分比分别为 5 8.9%、73.7%和 84 .2 % ,显著高于雷贝拉唑组 (32 .1%、5 4 .8%和 76 .2 % ,P <0 .0 0 1) ;胃内 pH中位值分别为 4 .2 9、5 .6 0和 6 .38,亦显著高于雷贝拉唑组 (2 .88、4 .2 6和 5 .77,P≤ 0 .0 0 1)。服药后首日及第 5天pH >4 .0超过 16h的志愿者埃索美拉唑组百分率分别为 6 3.9%和 88.9% ,亦显著高于雷贝拉唑 (33.3%和 6 1.1% ,P <0 .0 5 )。36名志愿者中 2 8名CYP 2C19基因型为强代谢型 ,8名为弱代谢型。两药对强代谢型或弱代谢型者胃泌酸的抑制差异无显著性 (P >0 .0 5 )。服药期间两组均未发生明显不良反应。结论　埃索美拉唑和雷贝拉唑均具有较强的抑制胃酸分泌效应 ,但在抑酸速度、抑酸强度和维持时间方面 ,4 0mg埃索美拉唑优于 10mg雷贝拉唑。两药     

Comparison of low-dose antacids,cimetidine, and placebo on 24-hour intragastric acidity in healthy volunteers

Low-dose aluminium (Al) antacids are effective in promoting ulcer healing and symptomatic relief in peptic ulcer patients, although the effect on intragastric acidity is very weak. In this randomized, double-blind study, 24-hr intragastric acidity was compared in 11 healthy volunteers, treated with a low-dose Al antacid regimen (1 tablet four times a day), cimetidine (800 mg at bedtime) and placebo, using the double-dummy technique. Standardized meals were given at 8am, noon, and 5pm. Medication was given 1 hr after meals and at bedtime. Intragastric acidity was recorded with a nasogastric monocrystant antimony pH catheter, connected to an ambulatory digital data recorder. No significant difference in intragastric acidity was observed between antacid and placebo treatment. Treatment with cimetidine reduced circadian and nocturnal (but not diurnal) intragastric acidity significantly, as compared to both placebo and antacid treatment. The results support the hypothesis that Al antacids promote peptic ulcer healing by other mechanisms than acid neutralization.     

Age- and gender-related differences in 24-hour esophageal pH monitoring of normal subjects

Twenty-four-hour esophageal pH monitoring is currently the most sensitive test for diagnosing gastroesophageal reflux. Little is known, however, about the effect of aging and gender on esophageal acid exposure in asymptomatic individuals. Thirty asymptomatic volunteers underwent 24-hr esophageal pH monitoring. Fifteen were <65 years (eight female, seven male) and 15 were 65 years (seven female, eight male). In this asymptomatic group no significant difference was seen by age, while males were found to have significantly more esophageal acid exposure than females. The need for sex-specific normal 24-hr pH monitoring values is suggested. Thirty percent of these asymptomatic subjects were abnormal by conventional 24-hr pH criteria. The clinical importance of these silent refluxers is unknown.